CDIP Antibody Cat. No.: 5059

Availability: In stock

$0.00

 Price Options

$0.00
psi-iconSpecifications
HOST SPECIES:Rabbit
SPECIES REACTIVITY: Human, Mouse
HOMOLOGY: Predicted species reactivity based on immunogen sequence: Rat: (100%), Bovine: (100%)
IMMUNOGEN: CDIP antibody was raised against a 19 amino acid synthetic peptide near the center of human CDIP.

The immunogen is located within amino acids 70 - 120 of CDIP.
TESTED APPLICATIONS: ELISA, IF, IHC-P, WB
APPLICATIONS: CDIP antibody can be used for detection of CDIP by Western blot at 0.25 - 0.5 μg/mL. Antibody can also be used for immunohistochemistry starting at 2.5 μg/mL. For immunofluorescence start at 20 μg/mL.

Antibody validated: Western Blot in human samples; Immunohistochemistry in mouse samples and Immunofluorescence in mouse samples. All other applications and species not yet tested.
POSITIVE CONTROL:1) Cat. No. 1303 - Human Brain Tissue Lysate

psi-iconProperties
PURIFICATION:CDIP Antibody is affinity chromatography purified via peptide column.
CLONALITY:Polyclonal
ISOTYPE:IgG
CONJUGATE:Unconjugated
PHYSICAL STATE:Liquid
BUFFER:CDIP Antibody is supplied in PBS containing 0.02% sodium azide.
CONCENTRATION:1 mg/mL
STORAGE CONDITIONS:CDIP antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

psi-iconAdditional Info
OFFICIAL SYMBOL:CDIP1
ALTERNATE NAMES:CDIP Antibody: I1, CDIP, LITAFL, C16orf5, Cell death-inducing p53-target protein 1, Cell death involved p53-target
ACCESSION NO.:NP_037531
PROTEIN GI NO.:118344450
GENE ID:29965
USER NOTE:Optimal dilutions for each application to be determined by the researcher.
psi-iconBackground and References
BACKGROUND:CDIP Antibody: The p53 tumor-suppressor gene integrates numerous signals that control cell life and death; loss of its functions contributes to the development of most cancers. CDIP is a novel pro-apoptotic target gene whose inhibition abrogates p53-mediated apoptotic responses. Overexpression of CDIP induced apoptosis in transfected cells while siRNA suppression of caspase-8 mRNA blocked this CDIP-induced apoptosis, indicating that the CDIP-dependent apoptosis pathway proceeds through extrinsic cell death pathway. CDIP may thus represent a novel target for drug design to maximize p53 response and sensitize tumor cells to cancer therapy. Multiple isoforms of CDIP are known to exist.
REFERENCES:1) Guimaraes DP and Hainaut P. TP53: a key gene in human cancer. Biochimie2002; 84:83-93.
2) Brown L, Ongusaha PP, Kim H-H, et al. CDIP, a novel pro-apoptotic gene, regulates TNFa-mediated apoptosis in a p53-dependent manner. EMBO J.2007; 26:3410-22.

ANTIBODIES FOR RESEARCH USE ONLY.

For additional information, visit ProSci's Terms & Conditions Page.